CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma

Padmanee Sharma(The University of Texas MD Anderson Cancer Center), Eiichi Sato(Shinmatsudo Central General Hospital), Yu Shen(University of Florida), Sijin Wen(The University of Texas MD Anderson Cancer Center), Dean F. Bajorin(Memorial Sloan Kettering Cancer Center), Sacha Gnjatic(Tisch Hospital), Lloyd J. Old(Gynecologic Oncology Group), Sachiko Yamada(Saiseikai Ibaraki Hospital), Achim A. Jungbluth(Gynecologic Oncology Group), Harry W. Herr(Memorial Sloan Kettering Cancer Center), Victor E. Reuter(Memorial Sloan Kettering Cancer Center)
Proceedings of the National Academy of Sciences
February 27, 2007
10.1073/pnas.0611618104
Cited by 517

Related Papers

Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Clinical-grade computational pathology using weakly supervised deep learning on whole slide images
|Nature Medicine|2019|2.6k